Metabolic

Tirzepatide

GIP and GLP-1 receptor agonist

Studied forWeight management · type 2 diabetes2 4

FDA-approved products: Mounjaro for type 2 diabetes; Zepbound for eligible adults with obesity/overweight and for moderate-to-severe OSA in adults with obesity.

What does it do?

A dual GIP/GLP-1 medicine with product-specific approvals for diabetes, weight management and obstructive sleep apnea in adults with obesity.

Approved & studied uses

Type 2 diabetes

Mounjaro indication; prescribing depends on age and formulation.

Weight management

Zepbound is approved for specified obesity/overweight populations.

Obstructive sleep apnea

Zepbound indication in adults with obesity and moderate-to-severe OSA.

Community uses Reported, unvalidated

Weight

Appetite, adiposity and maintenance; muscle preservation is not guaranteed.

Diabetes

Glycemic control and insulin-resistance research.

Cardiometabolic

BP, lipids and risk outcomes; distinguish measured markers from approved indications.

Reasons people report using it; these do not establish benefit.14

Evidence limits

View research →

Averages vary by population, adherence and analysis method.1

2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Key safety information

All risks →

Common effects

Nausea, diarrhea, vomiting, constipation and abdominal symptoms.2

FDA-approved products: Mounjaro for type 2 diabetes; Zepbound for eligible adults with obesity/overweight and for moderate-to-severe OSA in adults with obesity.

Molecular information

2 5

Amino-acid sequence

Residue count only · sequence not verified2 5

An exact sequence has not been verified for this formulation.

Length39 amino acids

Molecular weight · Da4813.53 Da

Formula, sequence notation & identity

Molecular formulaC₂₂₅H₃₄₈N₄₈O₆₈2 5

Lipidated GIP/GLP-1 receptor agonist.

Chemical identity does not establish vial quality.

Pep-Pedia identity details

39 amino acids · 4,813.55 Da

His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Gly-Gly-Gly-Gly-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys

Reference description; checked chemical identity above takes precedence when available.14

Pharmacokinetics

How long does it stay in the body?

Data shown

Human data

Reported half-lifeApproximately 5 days2

Route / formulationSubcutaneous

Elapsed time 5 d

50%of reference level

Illustrative model using reported human data.

About 3% remaining after 25 d

Five half-lives in this simplified model. This is not a prediction of when effects stop.

Evidence and model details

Label estimate. Peak concentration occurs at 8–72 hours; peak time is not half-life.

Population: Healthy participants and patients with type 2 diabetes

100 × 2^{−time / half-life}. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.

What to expect

Study outcomes

Weight reduction over 72 weeks

SURMOUNT-1 mean changes were −15.0%, −19.5% and −20.9% at the three doses, versus −3.1% with placebo.1

Reported timelines

Reference & community

Source expectations

Appetite days 1–3; glucose 1–2 weeks; GI adaptation 2–4 weeks; weight changes over months, not guaranteed weekly loss.14

These are reported timelines, not a prediction of your response.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Topic

Primary goal

Fat loss88%

General wellness7%

Other: Weight loss1%

Muscle growth0%

Other: Weight loss 0%

The source hides 12 additional categories. Their labels and percentages are unavailable.

Number of responses to this question: not disclosed.

Source & limitations

The source displays “5096 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
This is a dated snapshot, not a live survey or current recommendation.

Protocols

Doses & schedules

Compare purpose, amount, route, frequency, and duration.

Source corrections

Research vials lack approved-product stability/efficacy assurance.

Scroll to compare all columns →

One row for each documented route and dose or dose range
Route	Dose	Frequency	Goal / evidence	Duration	References
SubQSubcutaneous	2.5 mg — initiation	Once weekly	Glycemic control: MounjaroProduct label	First 4 weeks	2
Population Adults with type 2 diabetes Context Initial step lasts 4 weeks; further 2.5-mg increases require at least 4 weeks. Prescriber-directed. Source dose wording 2.5 mg initiation; then 5 mg; maximum 15 mg
SubQSubcutaneous	5 mg — after initiation	Once weekly	Glycemic control: MounjaroProduct label	Not specified	2
Population Adults with type 2 diabetes Context Initial step lasts 4 weeks; further 2.5-mg increases require at least 4 weeks. Prescriber-directed. Source dose wording 2.5 mg initiation; then 5 mg; maximum 15 mg
SubQSubcutaneous	15 mg — labeled maximum	Once weekly	Glycemic control: MounjaroProduct label	Not specified	2
Population Adults with type 2 diabetes Context Initial step lasts 4 weeks; further 2.5-mg increases require at least 4 weeks. Prescriber-directed. Source dose wording 2.5 mg initiation; then 5 mg; maximum 15 mg
SubQSubcutaneous	5 mg target	Once weekly	Weight reduction: SURMOUNT-1Human study	72 weeks	1
Population Adults with obesity/overweight without diabetes Context Included a 20-week escalation period and lifestyle intervention. Source dose wording 5, 10 or 15 mg target
SubQSubcutaneous	10 mg target	Once weekly	Weight reduction: SURMOUNT-1Human study	72 weeks	1
Population Adults with obesity/overweight without diabetes Context Included a 20-week escalation period and lifestyle intervention. Source dose wording 5, 10 or 15 mg target
SubQSubcutaneous	15 mg target	Once weekly	Weight reduction: SURMOUNT-1Human study	72 weeks	1
Population Adults with obesity/overweight without diabetes Context Included a 20-week escalation period and lifestyle intervention. Source dose wording 5, 10 or 15 mg target
SubQ	2.5 mg weekly	Once weekly	Weight loss initiationReference report	12-24+ weeks minimum for full metabolic benefits	14
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Research vials lack approved-product stability/efficacy assurance. Source tabs Injectable
SubQ	5 mg weekly	Once weekly	Weight loss progressionReference report	12-24+ weeks minimum for full metabolic benefits	14
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Research vials lack approved-product stability/efficacy assurance. Source tabs Injectable
SubQ	7.5-10 mg weekly	Once weekly	Weight loss optimizationReference report	12-24+ weeks minimum for full metabolic benefits	14
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Research vials lack approved-product stability/efficacy assurance. Source tabs Injectable
SubQ	12.5-15 mg weekly	Once weekly	Maximum weight lossReference report	12-24+ weeks minimum for full metabolic benefits	14
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Research vials lack approved-product stability/efficacy assurance. Source tabs Injectable
SubQ	5-7.5 mg weekly	Once weekly	Diabetes management (mild)Reference report	12-24+ weeks minimum for full metabolic benefits	14
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Research vials lack approved-product stability/efficacy assurance. Source tabs Injectable
SubQ	10-15 mg weekly	Once weekly	Diabetes management (severe)Reference report	12-24+ weeks minimum for full metabolic benefits	14
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Research vials lack approved-product stability/efficacy assurance. Source tabs Injectable

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports14

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Injectable

Use period: 12-24+ weeks minimum for full metabolic benefits
Break: Medical supervision required for discontinuation

Reported timing

Any time of day, with or without food

Side effects & safety

Common effects

Nausea, diarrhea, vomiting, constipation and abdominal symptoms.

Thyroid warning

Contraindicated with personal/family MTC or MEN2; human tumor risk remains unknown.

Serious risks

Warnings include pancreatitis, dehydration-related kidney injury and severe gastrointestinal reactions.

Additional reported cautions

Reference reports14

Risks

GI effects, dehydration/kidney injury, pancreatitis, gallbladder disease, retinopathy, aspiration and hypoglycemia with other drugs; MTC/MEN2 contraindication.

Urgent

Severe abdominal pain, neck symptoms, persistent vomiting, low urine, edema, confusion, allergy or severe mood symptoms.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

12 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

Semaglutide

Avoidance reported

GLP-1 duplication.14

Reference report · Pep-Pedia label: Avoid Combination

Liraglutide

Avoidance reported

GLP-1 duplication.14

Reference report · Pep-Pedia label: Avoid Combination

Insulin

Caution reported

Hypoglycemia.14

Reference report · Pep-Pedia label: Monitor Combination

Oral contraceptives

Caution reported

Label requires backup/nonoral method around initiation/escalation.14

Reference report · Evidence context: Monitor combination

Insulin or sulfonylureas

Label warning

Hypoglycemia risk increases.2

Research context

Oral hormonal contraceptives

Label warning

Label advises non-oral or added barrier contraception for 4 weeks after initiation and each escalation.2

Research context

Oral medicines

Label warning

Delayed gastric emptying can alter absorption.2

Research context

Metformin

Unverified pairing

Established diabetes co-treatment.14

Reference report · Pep-Pedia label: Synergistic

CJC-1295

Unverified pairing

No proven muscle protection.14

Reference report · Pep-Pedia label: Compatible

Ipamorelin

Unverified pairing

No proven muscle protection.14

Reference report · Pep-Pedia label: Compatible

BPC-157

Unverified pairing

No proven GI protection.14

Reference report · Pep-Pedia label: Compatible

5-Amino-1MQ

Unverified pairing

Untested pairing.14

Reference report · Pep-Pedia label: Compatible

Reconstitution calculator

Enter your peptide amount and container size. Get a volume and a simple measurement scale.

1How much peptide do you have?

Total labeled amount of Tirzepatide.

2How much can your container hold?

Usable capacity of the destination vial or pen cartridge.

Measure with

1 dial unit = 0.01 mL on the documented V2 model. Confirm your pen’s scale.

Vial examples & blend contents Tirzepatide

Peptide reference

Listed amounts are packaging examples. Check your actual label.

Suggested final volume mL

Estimated water to add≈ mL

For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.

1 pen unit (one dial step)=

Measurement scale Conversions, not recommended doses
Pen units	Amount	Volume

Other simple scales

Convert a specific amount

Enter an amount to calculate its volume and device setting.

Amount to measure

Measuring-tool capacity

Calculation & assumptions

The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.

The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.

V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗

Reconstitution

Ready-to-use approved solution

Mounjaro pens and vials contain solution; no reconstitution.2

Formulation

Research powders are not interchangeable with the approved presentations.2

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Injectable

Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.

Solvents mentioned: Bacteriostatic water
Reported parameters: Source temperature: 2-8°C. · Reported post-preparation interval: 28 days.

The source describes gentle mixing and avoiding vigorous shaking.

Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceWhite to off-white lyophilized powderReported appearanceClear reconstituted solutionReported appearanceIntact vial seal and proper labelingReported appearanceProper storage maintenanceReported concernClumping, discoloration, or moistureReported concernPersistent cloudiness after reconstitutionReported variationUnusual crystallization patterns

Vial sizes

5mg8

10mg8

15mg8

20mg8

30mg8

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Refrigerated lifetime not established

The checked sources do not establish how long this research preparation remains stable and sterile after mixing.14

Ready-made products

Product-specific storage; no reconstitution.

Zepbound single-dose pen / vial

Normally 2–8°C. Unrefrigerated: up to 21 total days at ≤30°C. Do not freeze; protect from heat and light.15

Zepbound multi-dose vial / KwikPen

Unopened: 2–8°C, or up to 30 days at ≤30°C. In use: 2–8°C or ≤30°C. Discard at the earliest of 30 total days at room temperature, 30 days after first use, or four weekly doses.15

Full storage notes from Pep-Pedia

Injectable

Refrigerate 2-8°C, never freeze, protect from light

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Pen & syringe measurements Scales, capacity & references

Pen & syringe measurements

Device units measure volume. Concentration determines the amount in mg.

Open calculator ↗

V2 peptide pen

1 notch = 0.01 mL

Documented 1-unit V2 models

One dial increment: 1 unit
Cartridge capacity: 3 mL
Maximum setting: 60 units · 0.60 mL

Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.

U-100 syringe

1 unit = 0.01 mL

100 units = 1 mL

10 units: 0.10 mL
30-unit capacity: 0.30 mL
50 / 100-unit capacity: 0.50 / 1 mL

Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.

Other measuring tools

Use the mL scale

mL syringes and calibrated pipettes

0.01 mL: 10 µL
0.10 mL: 100 µL
Amount: mL × mg/mL

Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.

3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.

Device references

AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.

Research findings

Human trials

Source context

Research vials lack approved-product stability/efficacy assurance.

Compound identity & other names

A dual GIP/GLP-1 receptor agonist with approved prescription products for diabetes, weight management and certain sleep-apnea patients. Approved products have defined formulations; research powders do not share their approval.

Other names: Tirz · Mounjaro · Zepbound

FDA-approved products: Mounjaro for type 2 diabetes; Zepbound for eligible adults with obesity/overweight and for moderate-to-severe OSA in adults with obesity.

How it may work

Regulates glucose-dependent insulin, glucagon, gastric emptying and satiety.14

SURMOUNT-1: substantial weight reduction

Among 2,539 adults without diabetes, mean weight change at 72 weeks was −15.0%, −19.5% and −20.9% for 5, 10 and 15 mg, versus −3.1% for placebo, regardless of discontinuation.

An approved sleep-apnea indication

FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, with diet and physical activity. This does not establish treatment for every cause of sleep apnea.

Cardiovascular comparison met noninferiority

Primary events occurred in 12.2% with tirzepatide and 13.1% with dulaglutide (HR 0.92; 95.3% CI 0.83–1.01). Superiority was not demonstrated (p=0.09).

Source checks & newer research

Zepbound prescribing information: storage and contraception

Single-dose pen/vial: 21 total days ≤30°C. Multi-dose vial/KwikPen: discard after 30 days at room temperature, 30 days after first use, or four doses. Nonoral or barrier contraception for four weeks after initiation and every escalation. These rules do not validate research-vial expiry.

Approved product label15

Research areas and evidence gaps

Type 2 diabetes. Mounjaro indication; prescribing depends on age and formulation.2

Weight management. Zepbound is approved for specified obesity/overweight populations.4

Obstructive sleep apnea. Zepbound indication in adults with obesity and moderate-to-severe OSA.3

Averages vary by population, adherence and analysis method.
Research-vial labeling does not establish equivalence to Mounjaro or Zepbound.

Community reports Unvalidated

Pep-Pedia describes reduced appetite, earlier fullness and initial nausea. Its page is a secondary summary, not a verified cohort analysis.7

A secondary protocol description, not a clinical recommendation or a representative survey. Dose, product identity, other compounds and outcome reporting are not independently verified.

Search coverage and review status

The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.

Checked: 2026-10-12
Search: tirzepatide 2026 SURPASS CVOT site:pubmed.ncbi.nlm.nih.gov
Catalog: Pep-Pedia ↗ · 4 listed references retained

Targeted search, not an exhaustive systematic review.
Bibliography-only entries are retained for traceability and are not treated as verified findings.

AI-prepared summaries. Independent medical editorial review is pending.

References

Original sources and review status. Open a reference to read its summary.

15 sources

1SURMOUNT-1: tirzepatide for obesityTrial · 2022 · nejm.orgReview status not recorded

AI-PREPARED SUMMARY

A 72-week trial in 2,539 adults found mean weight changes of −15.0% to −20.9% across tirzepatide arms versus −3.1% with placebo.

SURMOUNT-1: substantial weight reduction

Among 2,539 adults without diabetes, mean weight change at 72 weeks was −15.0%, −19.5% and −20.9% for 5, 10 and 15 mg, versus −3.1% for placebo, regardless of discontinuation.

Original source

2Mounjaro FDA prescribing informationRegulator · 2026 · accessdata.fda.govReview status not recorded

AI-PREPARED SUMMARY

Defines the approved diabetes population, product presentations, contraindications and adverse effects. The label applies to Mounjaro, not research powders.

Original source

3FDA: first medication for obstructive sleep apneaRegulator · 2024 · fda.govReview status not recorded

AI-PREPARED SUMMARY

Zepbound's additional indication covers moderate-to-severe OSA in adults with obesity alongside diet and activity.

An approved sleep-apnea indication

FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, with diet and physical activity. This does not establish treatment for every cause of sleep apnea.

Original source

4FDA: Zepbound weight-management approvalRegulator · 2023 · fda.govReview status not recorded

AI-PREPARED SUMMARY

FDA approved Zepbound for chronic weight management in eligible adults with obesity or overweight and a related condition.

Original source

5PubChem: tirzepatide chemical identityRegistry · 2026 · pubchem.ncbi.nlm.nih.govReview status not recorded

AI-PREPARED SUMMARY

Describes the 39-residue linear peptide and its linked C20 fatty diacid.

Original source

6SURPASS-CVOT: cardiovascular outcomes versus dulaglutideTrial · 2025 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

Published December 2025. In type 2 diabetes with ASCVD, tirzepatide met noninferiority but not superiority for MACE versus dulaglutide.

Cardiovascular comparison met noninferiority

Primary events occurred in 12.2% with tirzepatide and 13.1% with dulaglutide (HR 0.92; 95.3% CI 0.83–1.01). Superiority was not demonstrated (p=0.09).

Additional research · Checked 2026-10-12

Original source

7Pep-Pedia: tirzepatide — community referenceCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Accessed October 12, 2026. Reports commonly discussed protocols; these schedules are unvalidated descriptions, not evidence of safety or efficacy.

Original source

8Research catalog: labeled vial examplesCatalog · 2026 · pepticorebio.comCatalog checked

AI-PREPARED SUMMARY

Catalog lists research vials including 5, 10, 15, 20, 30 mg. Seller labels only: contents and suppliers are not independently verified or endorsed, and these are not market-frequency estimates.

Original source

9SURMOUNT-2 T2DM Trial (2023)Research reference · 2023 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: SURMOUNT-2 reportedly produced 15.7% weight loss at 15 mg over 72 weeks in adults with diabetes and obesity.

Reported population / model
938 adults with T2DM and obesity

Reported study details
72-week duration

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

10SURPASS-CVOT: cardiovascular outcomes versus dulaglutide (2025)Trial · 2025 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

Published December 2025. In type 2 diabetes with ASCVD, tirzepatide met noninferiority but not superiority for MACE versus dulaglutide.

Pep-Pedia bibliography; reconciled with an existing checked primary-source record · Checked 2026-10-12

Original source

11SURMOUNT-1 Phase 3 Trial (2022)Research reference · 2022 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The source reports 22.5% versus 2.4% weight loss, a different analysis from the main treatment-regimen estimate; estimands must not be mixed.

Reported population / model
2,539 adults with obesity

Reported study details
72-week study · Multiple dose levels

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

12SURPASS Clinical Program (2021-2022)Research reference · 2022 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The program compared specified doses and medicines, not every diabetes treatment; claims of universal superiority exceed the comparisons tested.

Reported population / model
Multiple Phase 3 trials

Reported study details
>13,000 T2DM patients · Head-to-head comparisons

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

13Pep-Pedia: Tirzepatide — reported pharmacokineticsReference estimate; not independently verified human PKCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Lists a half-life of 5 days and a peak time of 1 day. Stated attribution: FDA Mounjaro Label. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.

Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12

Original source

14Pep-Pedia: Tirzepatide — route-specific referenceReference page checked; underlying claims require separate verification.Community · Checked 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.

Content coverage audit · Checked 2026-10-12

Original source

15Zepbound prescribing information: storage and contraceptionRegulator · 2026 · pi.lilly.comPrimary source checked

AI-PREPARED SUMMARY

Zepbound prescribing information: storage and contraception

Additional primary-source check · Checked 2026-10-12

Original source

What does it do?

Approved & studied uses

Type 2 diabetes

Weight management

Obstructive sleep apnea

Community uses Reported, unvalidated

Weight

Diabetes

Cardiometabolic

Evidence limits

Key safety information

Common effects

Molecular information

Amino-acid sequence

How long does it stay in the body?

What to expect

Study outcomes

Weight reduction over 72 weeks

Reported timelines

Source expectations

Experience

Duration of use

Age range

Gender

Primary goal

Effectiveness

Side effects

Dosage frequency

Would recommend

How discovered

Doses & schedules

Cycles & timing

Injectable

Reported timing

Side effects & safety

Common effects

Thyroid warning

Serious risks

Additional reported cautions

Risks

Urgent

Combinations & interactions

Semaglutide

Liraglutide

Insulin

Oral contraceptives

Insulin or sulfonylureas

Oral hormonal contraceptives

Oral medicines

Metformin

CJC-1295

Ipamorelin

BPC-157

5-Amino-1MQ

Reconstitution calculator

Ingredients per unit

Reconstitution

Formulation

Injectable

Vial sizes

Storage after mixing

Reconstituted research vials

Ready-made products

Zepbound single-dose pen / vial

Zepbound multi-dose vial / KwikPen

Pen & syringe measurements

1 notch = 0.01 mL

1 unit = 0.01 mL

Use the mL scale

Research findings

Source context

SURMOUNT-1: substantial weight reduction

An approved sleep-apnea indication

Cardiovascular comparison met noninferiority

Source checks & newer research

Zepbound prescribing information: storage and contraception

References

Related profiles